Folate deficiency is frequently associated with elevated plasma Hcy concentration – hyperhomocysteinemia – that is considered a recognized risk factor for cardiovascular disease (CVD) and may also be associated with hypertension.
Quatrefolic® offers tangible advantages versus folic acid and can promote healthier heart life reaching better blood levels of folate directly translates to lower homocysteine levels, especially for people with MTHFR polymorphism. In fact, while folic acid must be first converted into 5-MTHF by a multi-enzymatic steps process, Quatrefolic® is the biologically active form of folate that completely bypasses this metabolic route helping people with polymorphisms in folate-related enzymes, such as the polymorphism of the enzyme MTHFR (methylentetrahydrofolate reductase). These genetic alterations can lead to an increase in homocysteine blood levels.
The homocysteine-lowering and -normalizing effect of Quatrefolic®, in comparison with a high dosage of folic acid in hypertensive subjects at low cardiovascular risk, has been tested by Mazza et al in 2016, supporting Quatrefolic® as the best and healthier solution for right folate supplementation.
The treatment with 400 μg of Quatrefolic® (plus B6, and B12) versus highly dosed folic acid (5 mg/day) was significantly effective and the ideal HCys level was reached in 55.8% of cases in the Quatrefolic® group, significantly higher than in controls.
Discovering the advantages of the active folate supplementation and Quatrefolic® health applications is today even easier, thanks to the recent book written by Prof. Ingrosso & Perna, “The innovative Folate – 5-MTHF in Human Health” dedicated to the folate world and the key advantages of Quatrefolic®.